Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.47 |
| ▸ | DDIT3 | P35638 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21772288 | 0.90 | AKR1C3 (0.54) | MEN1KMT2AHSD11B1PKMTDP1 | |
| SCHEMBL29764451 | 0.86 | HSD11B1 (0.58) | MEN1KMT2AHSD11B1TDP1MCOLN3 | |
| SCHEMBL16912992 | 0.84 | MEN1 (0.61) | MEN1KMT2APKMTDP1MCOLN3 | |
| SCHEMBL14095893 | 0.84 | MEN1 (0.61) | MEN1KMT2APKMTDP1MCOLN3 | |
| SCHEMBL12793343 | 0.84 | USP2 (0.71) | MEN1KMT2AHSD11B1TDP1LMNA | |
| SCHEMBL11306227 | 0.83 | PKM (0.69) | MEN1KMT2APKMUSP2ALDH1A1 | |
| SCHEMBL5249802 | 0.83 | LMNA (0.71) | MEN1KMT2AHSD11B1PKMLMNA | |
| SCHEMBL15800491 | 0.83 | HSD11B1 (0.58) | MEN1KMT2AHSD11B1PKMTDP1 | |
| SCHEMBL4940237 | 0.83 | ALDH1A1 (0.64) | MEN1KMT2AHSD11B1PKMLMNA | |
| SCHEMBL16913002 | 0.83 | MEN1 (0.60) | MEN1KMT2APKMTDP1MCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2024-12-19 | — | — | US | disclosed |
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | THE UNIVERSITY OF CHICAGO (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3993802-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114340634-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3946301-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | The University of Chicago (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| WO-2009056693-A1 | NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008099073-A1 | N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | MEN1 2924/4885KMT2A 4122/4885HSD11B1 2982/4885 |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | MYLK, MFAP1, FIBP | MEN1 4571/4885KMT2A 3269/4885HSD11B1 4073/4885 |
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | MEN1 1663/4885KMT2A 448/4885HSD11B1 2856/4885 |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | PDE7A, PDE7B, PDE3B | MEN1 3519/4885KMT2A 3266/4885HSD11B1 311/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | MEN1 1745/4885KMT2A 141/4885HSD11B1 2246/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | MEN1 3367/4885KMT2A 1671/4885HSD11B1 2577/4885 |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | MYLK, MFAP1, FIBP | MEN1 4571/4885KMT2A 3269/4885HSD11B1 4073/4885 |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | MEN1 2924/4885KMT2A 4122/4885HSD11B1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.